Movement Alert｜GenScript Biotech Rises 5.07% in Regular Trading, Legend Biotech In-Vivo CAR-T Data Presented at EHA Conference

Market Focus06-12

On June 12, GenScript Biotech rose 5.07% in regular trading, trading at HK$12.44/share, with turnover of HK$520 million. The rally coincides with the ongoing EHA (European Hematology Association) annual meeting where subsidiary Legend Biotech is presenting breakthrough clinical data.

Legend Biotech is delivering a Late-Breaking Oral Presentation at the EHA conference (June 11-14) showcasing preliminary Phase 1 clinical data for LB2501, a CD19/CD20 dual-target in-vivo CAR-T therapy for relapsed/refractory B-cell non-Hodgkin lymphoma. Previously disclosed data showed 100% overall response rate and 83.3% complete remission rate in the second dose-level cohort of 6 patients, with no dose-limiting toxicities or serious adverse events observed. Analysts have characterized LB2501 as a disruptive breakthrough in cell therapy with the potential to make CAR-T treatments broadly accessible by eliminating the need for lymphodepletion chemotherapy and supporting outpatient administration.

The broader Life Sciences Tools and Services sector also traded positively, with Wuxi XDC up 4.80%, Wuxi Biologics up 3.54%, and XtalPi up 2.78%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1183684361?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-12 15:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1183684361","market":"hk","top_or_hot":-1,"title":"Movement Alert｜GenScript Biotech Rises 5.07% in Regular Trading, Legend Biotech In-Vivo CAR-T Data Presented at EHA Conference","media":"Market Focus","content":"<p><p>On June 12, GenScript Biotech rose 5.07% in regular trading, trading at HK$12.44/share, with turnover of HK$520 million. The rally coincides with the ongoing EHA (European Hematology Association) annual meeting where subsidiary Legend Biotech is presenting breakthrough clinical data.</p><p>Legend Biotech is delivering a Late-Breaking Oral Presentation at the EHA conference (June 11-14) showcasing preliminary Phase 1 clinical data for LB2501, a CD19/CD20 dual-target in-vivo CAR-T therapy for relapsed/refractory B-cell non-Hodgkin lymphoma. Previously disclosed data showed 100% overall response rate and 83.3% complete remission rate in the second dose-level cohort of 6 patients, with no dose-limiting toxicities or serious adverse events observed. Analysts have characterized LB2501 as a disruptive breakthrough in cell therapy with the potential to make CAR-T treatments broadly accessible by eliminating the need for lymphodepletion chemotherapy and supporting outpatient administration.</p><p>The broader Life Sciences Tools and Services sector also traded positively, with Wuxi XDC up 4.80%, Wuxi Biologics up 3.54%, and XtalPi up 2.78%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜GenScript Biotech Rises 5.07% in Regular Trading, Legend Biotech In-Vivo CAR-T Data Presented at EHA Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜GenScript Biotech Rises 5.07% in Regular Trading, Legend Biotech In-Vivo CAR-T Data Presented at EHA Conference\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-12 15:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 12, GenScript Biotech rose 5.07% in regular trading, trading at HK$12.44/share, with turnover of HK$520 million. The rally coincides with the ongoing EHA (European Hematology Association) annual meeting where subsidiary Legend Biotech is presenting breakthrough clinical data.</p><p>Legend Biotech is delivering a Late-Breaking Oral Presentation at the EHA conference (June 11-14) showcasing preliminary Phase 1 clinical data for LB2501, a CD19/CD20 dual-target in-vivo CAR-T therapy for relapsed/refractory B-cell non-Hodgkin lymphoma. Previously disclosed data showed 100% overall response rate and 83.3% complete remission rate in the second dose-level cohort of 6 patients, with no dose-limiting toxicities or serious adverse events observed. Analysts have characterized LB2501 as a disruptive breakthrough in cell therapy with the potential to make CAR-T treatments broadly accessible by eliminating the need for lymphodepletion chemotherapy and supporting outpatient administration.</p><p>The broader Life Sciences Tools and Services sector also traded positively, with Wuxi XDC up 4.80%, Wuxi Biologics up 3.54%, and XtalPi up 2.78%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01548","symbol_name":"金斯瑞生物科技","start_time":0,"source_url":"","article_id":"1183684361","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1183684361","pubTimestamp":1781249489,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 12, GenScript Biotech rose 5.07% in regular trading, trading at HK$12.44/share, with turnover of HK$520 million. The rally coincides with the ongoing EHA (European Hematology Association)...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01548":"金斯瑞生物科技"},"translate_title":"动静提示|金斯瑞生物常规交易涨5.07%传奇生物体内CAR-T数据亮相EHA会议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":1},"content_text":"On June 12, GenScript Biotech rose 5.07% in regular trading, trading at HK$12.44/share, with turnover of HK$520 million. The rally coincides with the ongoing EHA (European Hematology Association) annual meeting where subsidiary Legend Biotech is presenting breakthrough clinical data.Legend Biotech is delivering a Late-Breaking Oral Presentation at the EHA conference (June 11-14) showcasing preliminary Phase 1 clinical data for LB2501, a CD19/CD20 dual-target in-vivo CAR-T therapy for relapsed/refractory B-cell non-Hodgkin lymphoma. Previously disclosed data showed 100% overall response rate and 83.3% complete remission rate in the second dose-level cohort of 6 patients, with no dose-limiting toxicities or serious adverse events observed. Analysts have characterized LB2501 as a disruptive breakthrough in cell therapy with the potential to make CAR-T treatments broadly accessible by eliminating the need for lymphodepletion chemotherapy and supporting outpatient administration.The broader Life Sciences Tools and Services sector also traded positively, with Wuxi XDC up 4.80%, Wuxi Biologics up 3.54%, and XtalPi up 2.78%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"conferences","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1183684361","isCrawlerRequest":true}